Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Novartis has won an approval to sell its landmark CAR-T therapy Kymriah in Japan at a discount price as it continues its slow rollout …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
